Bayer AG/ DE000BAY0017 /
8/29/2024 4:34:33 PM | Chg. - | Volume | Bid8/26/2024 | Ask5:22:29 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
27.92EUR | - | 575 Turnover: 16,054.22 |
-Bid Size: - | -Ask Size: - | 27.42 bill.EUR | 0.39% | - |
GlobeNewswire
8/2
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire
7/11
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire
5/30
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
5/30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
5/2
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
4/18
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
4/16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
4/11
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
3/25
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
3/6
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
3/4
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
2/13
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...